I do not believe so. I feel that there is a genuine increase in thrombogenicity associated with the viral vector for the COVID-19 vaccines. It seems to affect Johnson and Johnson as well as Astra Zeneca.

Interesting Rajkumar Rajendram

Nowadays the normal incidence of thrombogenesis in the population is higher (see the following table: from 59.5 to 1518.7 per 100.000 population) than among people treated with the AstraZeneca vaccine (0.344 per 100.000 population). Demagogy and populism on TV is doing a lot of damage to health care.

Article Global Burden of Thrombosis: Table.: Epidemiologic Aspects

https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood

Dear colleaque such hype occurs as a results of media which exaggurate rare disadvanteges and ignore high advantages like return country to normalization,marked decrease hospitalization and number of deaths.Media either local or outside due to competions between companies producing vaccines

I agree With Salameh Barhoom